Æó·Å±¸±Õ ¹é½Å ½ÃÀå : ¹é½Å À¯Çüº°, ´ë»ó Áý´Üº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°
Pneumococcal Vaccines Market, By Vaccine Type, By Target Population, By Route of Administration, By Distribution Channel, By Geography
»óǰÄÚµå : 1672784
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,358,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,891,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,130,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Æó·Å±¸±Õ ¹é½Å ½ÃÀåÀº 2025³â¿¡´Â 93¾ï 8,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 132¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 5.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ 2024 2025³â ½ÃÀå ±Ô¸ð 93¾ï 8,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 5.10% 2032³â °¡Ä¡ ¿¹Ãø 132¾ï 9,000¸¸ ´Þ·¯
µµÇ¥. Æó·Å±¸±Õ ¹é½Å ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
Pneumococcal Vaccines Market-IMG1

¼¼°èÀÇ Æó·Å±¸±Õ ¹é½Å ½ÃÀå ¼ºÀåÀº Àü ¼¼°è Æó·Å±¸±Õ ÁúȯÀÇ ¹ßº´·ü Áõ°¡¿Í °¢±¹ Á¤ºÎÀÇ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æó·Å±¸±Õ ¹é½Å Á¢Á¾¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª Æó·Å±¸±Õ ¹é½ÅÀÇ °³¹ß ¹× »ý»ê°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àú·ÅÇϰí È¿°úÀûÀÎ ¹é½ÅÀ» °³¹ßÇϱâ À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸ Ȱµ¿Àº °¡±î¿î ¹Ì·¡¿¡ »õ·Î¿î ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°èÀÇ Æó·Å±¸±Õ ¹é½Å ½ÃÀå ¼ºÀåÀº ÁÖ·Î Æó·Å±¸±Õ¿¡ ÀÇÇÑ Æó·Å, ¼ö¸·¿° ¹× ±âŸ ½É°¢ÇÑ °¨¿°ÁõÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é Æó·ÅÀº 5¼¼ ¹Ì¸¸ ¾î¸°ÀÌÀÇ »ç¸Á ¿øÀÎ »óÀ§ 5À§ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ ±¹°¡ ¿¹¹æ Á¢Á¾ ÀÏÁ¤À» ÅëÇØ ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥À» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎ ÀÚ±Ý ¹× ±¸»ó Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª Æó·Å±¸±Õ ¹é½ÅÀÇ ³ôÀº ¿¬±¸°³¹ß ¹× Á¦Á¶ºñ¿ëÀº ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î ´Ù°¡¼º Æó·Å±¸±Õ Á¦Á¦ÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Æò°¡Çϱâ À§ÇÑ ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀ̶ó´Â Á¡Àº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÅÈï ±¹°¡Àº ÇコÄɾî ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖÀ¸¸ç, ½ÃÀå ÁøÃâ±â¾÷¿¡°Ô Å« ±âȸ°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ Æó·Å±¸±Õ ¹é½Å ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è Æó·Å±¸±Õ ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ °³¿äÀ» ±â¾÷ °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ ±âÁØÀ¸·Î Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

ÁÖ¿ä ±â¾÷Àº Pfizer Inc., Merck & Co., GSK plc., and Sanofi µîÀÔ´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°èÀÇ Æó·Å±¸±Õ ¹é½Å ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ Æó·Å±¸±Õ ¹é½Å ½ÃÀå, ¹é½Å À¯Çüº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦5Àå ¼¼°èÀÇ Æó·Å±¸±Õ ¹é½Å ½ÃÀå, ´ë»ó Áý´Üº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦6Àå ¼¼°èÀÇ Æó·Å±¸±Õ ¹é½Å ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦7Àå ¼¼°èÀÇ Æó·Å±¸±Õ ¹é½Å ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦8Àå ¼¼°èÀÇ Æó·Å±¸±Õ ¹é½Å ½ÃÀå, Áö¿ªº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

Á¦11Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pneumococcal Vaccines Market is estimated to be valued at USD 9.38 Bn in 2025 and is expected to reach USD 13.29 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 9.38 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.10% 2032 Value Projection: USD 13.29 Bn
Figure. Pneumococcal Vaccines Market Share (%), By Region 2025
Pneumococcal Vaccines Market - IMG1

Global pneumococcal vaccines market growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments. Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.

Market Dynamics:

Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.

Key features of the study:

This report provides in-depth analysis of the global pneumococcal vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pneumococcal vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2020-2032, (USD Bn)

5. Global Pneumococcal Vaccines Market, By Target Population, 2020-2032, (USD Bn)

6. Global Pneumococcal Vaccines Market, By Route of Administration, 2020-2032, (USD Bn)

7. Global Pneumococcal Vaccines Market, By Distribution Channel, 2020-2032, (USD Bn)

8. Global Pneumococcal Vaccines Market, By Region, 2020 - 2032, (USD Bn)

9. Competitive Landscape

10. Analyst Recommendations

11. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â